MYGN
Myriad Genetics, Inc.

2,117
Loading...
Loading...
News
all
press releases
Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker
ILMN partners with pharma leaders to advance KRAS-focused companion diagnostics through its TruSight Oncology platform.
Zacks·23h ago
News Placeholder
More News
News Placeholder
Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?
Myriad Genetics expands oncology testing and launches new diagnostics, but inflation and rising competition weigh on its outlook.
Zacks·17d ago
News Placeholder
MYGN Stock Might Gain on The Lancet Study Backing Precise MRD
Myriad Genetics' Precise MRD study in The Lancet shows ctDNA detection power in oligometastatic ccRCC, supporting oncology growth plans.
Zacks·25d ago
News Placeholder
MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain?
Myriad Genetics' GeneSight test outperforms treatment-as-usual in major depression, raising hopes for broader adoption and renewed stock momentum.
Zacks·28d ago
News Placeholder
Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·2mo ago
News Placeholder
Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates
Myriad (MYGN) delivered earnings and revenue surprises of +600.00% and +5.55%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches
TEM expands its precision medicine arsenal with AI-powered tools, liquid biopsy tech and genome sequencing.
Zacks·3mo ago
News Placeholder
Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?
Zacks·4mo ago
News Placeholder
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?
Zacks·4mo ago
News Placeholder
Myriad Genetics Shares Tank 41% On Analyst Downgrades, Weaker Guidance: Yet Retail Investors Remain Bullish
Analysts, including those from Wells Fargo, UBS, Raymond James, and Craig-Hallum, slashed their price targets and expressed concerns over the company's growth and execution challenges.
Stocktwits·5mo ago

Latest MYGN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.